POAI Fundamental Analysis - PREDICTIVE ONCOLOGY INC

Fundamental Rating

POAI gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. POAI may be in some trouble as it scores bad on both profitability and health. POAI is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.
In the past year POAI has reported a negative cash flow from operations.
POAI had negative earnings in each of the past 5 years.
POAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

POAI's Return On Assets of -2688.13% is on the low side compared to the rest of the industry. POAI is outperformed by 98.40% of its industry peers.

		Industry Rank	Sector Rank
ROA	-2688.13%
ROE	N/A
ROIC	N/A

ROA(3y)-150.57%

ROA(5y)-139.82%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 50.26%, POAI perfoms like the industry average, outperforming 44.92% of the companies in the same industry.
In the last couple of years the Gross Margin of POAI has declined.
POAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	50.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.14%

GM growth 5Y-4.67%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
POAI has more shares outstanding than it did 1 year ago.
POAI has more shares outstanding than it did 5 years ago.
There is no outstanding debt for POAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

POAI has an Altman-Z score of -157.16. This is a bad value and indicates that POAI is not financially healthy and even has some risk of bankruptcy.
POAI has a worse Altman-Z score (-157.16) than 96.26% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-157.16

ROIC/WACCN/A

WACC8.8%

2.3 Liquidity

A Current Ratio of 0.01 indicates that POAI may have some problems paying its short term obligations.
With a Current ratio value of 0.01, POAI is not doing good in the industry: 99.47% of the companies in the same industry are doing better.
POAI has a Quick Ratio of 0.01. This is a bad value and indicates that POAI is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.01, POAI is not doing good in the industry: 99.47% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.01
Quick Ratio	0.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for POAI have decreased strongly by -163.00% in the last year.
Looking at the last year, POAI shows a very negative growth in Revenue. The Revenue has decreased by -47.20% in the last year.
POAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.86% yearly.

EPS 1Y (TTM)-163%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1379.27%

Revenue 1Y (TTM)-47.2%

Revenue growth 3Y4.57%

Revenue growth 5Y2.86%

Sales Q2Q%-98.96%

3.2 Future

Based on estimates for the next years, POAI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.17% on average per year.
Based on estimates for the next years, POAI will show a very strong growth in Revenue. The Revenue will grow by 158.10% on average per year.

EPS Next Y99.58%

EPS Next 2Y41.51%

EPS Next 3Y26.17%

EPS Next 5YN/A

Revenue Next Year569.48%

Revenue Next 2Y232.87%

Revenue Next 3Y158.1%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

POAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
POAI is valuated quite expensively with a Price/Forward Earnings ratio of 72.92.
Based on the Price/Forward Earnings ratio, POAI is valued a bit cheaper than 66.31% of the companies in the same industry.
POAI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.31.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	72.92

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as POAI's earnings are expected to grow with 26.17% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.51%

EPS Next 3Y26.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for POAI!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (12/11/2025, 8:01:54 PM)

After market: 5.8945 -0.06 (-0.93%)

5.95

+0.03 (+0.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-14 2025-11-14

Earnings (Next)03-30 2026-03-30

Inst Owners0.15%

Inst Owner Change0%

Ins Owners3.21%

Ins Owner Change20.39%

Market Cap88.66M

Revenue(TTM)728.20K

Net Income(TTM)-84.33M

Analysts43.33

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-99.79%

Min Revenue beat(2)-99.82%

Max Revenue beat(2)-99.76%

Revenue beat(4)1

Avg Revenue beat(4)-55.24%

Min Revenue beat(4)-99.82%

Max Revenue beat(4)71.43%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	72.92
P/S	121.75
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-120.64

EYN/A

EPS(NY)0.08

Fwd EY1.37%

FCF(TTM)-0.53

FCFYN/A

OCF(TTM)-0.53

OCFYN/A

SpS0.05

BVpS-5.2

TBVpS-5.2

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-2688.13%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	50.26%
FCFM	N/A

ROA(3y)-150.57%

ROA(5y)-139.82%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-9.14%

GM growth 5Y-4.67%

F-Score4

Asset Turnover0.23

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0%
Cap/Sales	0%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.01
Quick Ratio	0.01
Altman-Z	-157.16

F-Score4

WACC8.8%

ROIC/WACCN/A

Cap/Depr(3y)20.65%

Cap/Depr(5y)33.78%

Cap/Sales(3y)11.77%

Cap/Sales(5y)26.34%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-163%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1379.27%

EPS Next Y99.58%

EPS Next 2Y41.51%

EPS Next 3Y26.17%

EPS Next 5YN/A

Revenue 1Y (TTM)-47.2%

Revenue growth 3Y4.57%

Revenue growth 5Y2.86%

Sales Q2Q%-98.96%

Revenue Next Year569.48%

Revenue Next 2Y232.87%

Revenue Next 3Y158.1%

Revenue Next 5YN/A

EBIT growth 1Y21.86%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y42.55%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y40.91%

OCF growth 3YN/A

OCF growth 5YN/A

PREDICTIVE ONCOLOGY INC / POAI FAQ

What is the ChartMill fundamental rating of PREDICTIVE ONCOLOGY INC (POAI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to POAI.

What is the valuation status for POAI stock?

ChartMill assigns a valuation rating of 2 / 10 to PREDICTIVE ONCOLOGY INC (POAI). This can be considered as Overvalued.

What is the profitability of POAI stock?

PREDICTIVE ONCOLOGY INC (POAI) has a profitability rating of 0 / 10.

PREDICTIVE ONCOLOGY INC (POAI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

PREDICTIVE ONCOLOGY INC / POAI FAQ

What is the ChartMill fundamental rating of PREDICTIVE ONCOLOGY INC (POAI) stock?

What is the valuation status for POAI stock?

What is the profitability of POAI stock?